Reimbursement not recommended at the submitted price.
The NCPE does not recommend reimbursement of lixisenatide for patients with type 2 diabetes mellitus at the submitted price.
The NCPE believe that apixaban is cost effective for this indication
Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland PCV13 is the most cost-effective option if the analysis is based on a serotype distribution reflecting 2011 data. download document
Cost-effectiveness of Oncotype DX® to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positive, early-stage breast cancer in Ireland.
Following a price revision we now consider Fingolimod (Gilenya®) a cost-effective therapy for the treatment of relapsing-remitting multiple sclerosis patients in the Irish healthcare setting.
Cost effectiveness analysis of a universal infant rotavirus vaccination programme in Ireland
Health Technology Assessment (HTA) of population-based colectoral cancer screening programme in Ireland.
We do not believe that glucosamine sulfate (DONA®) is a cost effective therapy for the treatment of osteoarthritis in the Irish Healthcare setting.